New Research Could Lead to More Effective Chemotherapy

Art by Ross Maute and Eric Pipkin This images show a platinum-based molecule (top) and gold-based molecule (bottom) killing cancer cells.

FAYETTEVILLE, Ark. – An international team of researchers led by Hudson Beyzavi of the University of Arkansas, is studying the use of platinum and gold to enable more effective forms of chemotherapy.

Gold-based complexes are not currently used in commercial cancer therapies. Cisplatin, a platinum-based chemotherapy drug, is commercially available, but it has several drawbacks.

“Biological importance of platinum complexes in medicinal chemistry has attracted considerable attention due to the wide-spread therapeutic activities of cisplatin,” the researchers said. “However, the anticancer properties of cisplatin are believed to be limited by major drawbacks, including intrinsic or acquired resistances and several toxicities.”

Beyzavi, an assistant professor in the Department of Chemistry and Biochemistry at the University of Arkansas, explained that new platinum- and gold-based drug candidates could lead to therapies that are more effective and less prone to resistance than cisplatin, which means patients could take lower doses, minimizing the risk of side effects. He said that another goal of this research is to expand the scope of cancer cells that can be targeted.

The researchers used computer simulations to design several different platinum-based molecular structures and test how these anti-cancer agents would bind to the DNA of cancer cells.

To synthesize the new gold-based molecular complexes, the researchers used structures called ligands — groups of atoms which can be added to metals. They focused on two types, isocyanide and thiolate ligands.

After the researchers had identified several promising molecular structures, Beyzavi synthesized the platinum and gold complexes. His collaborators then tested these drug candidates in the laboratory, exposing them to human lung, ovarian and breast cancer cell lines. Experimental results showed that these molecules were able to induce natural cell death by binding to the DNA of cancer cells. The researchers compared these new drug candidates to cisplatin and found that three of them were significantly more effective.

The team recently published their findings in the New Journal of Chemistry and Applied Organometallic Chemistry. Their articles were featured on the cover of both journals.

About the J. William Fulbright College of Arts and Sciences: Fulbright College is the largest and most academically diverse unit on campus with 19 departments and more than 30 academic programs and research centers. The college provides the core curriculum for all University of Arkansas students and is named for J. William Fulbright, former university president and longtime U.S. senator.

About the University of Arkansas: The University of Arkansas provides an internationally competitive education for undergraduate and graduate students in more than 200 academic programs. The university contributes new knowledge, economic development, basic and applied research, and creative activity while also providing service to academic and professional disciplines. The Carnegie Foundation classifies the University of Arkansas among only 2 percent of universities in America that have the highest level of research activity. U.S. News & World Report ranks the University of Arkansas among its top American public research universities. Founded in 1871, the University of Arkansas comprises 10 colleges and schools and maintains a low student-to-faculty ratio that promotes personal attention and close mentoring.

This story originally appeared in the University of Arkansas’ Newswire publication. Please visit news.uark.edu for more stories like this.